Esophageal cancer is a highly lethal malignancy, representing 5% of all cancer-related deaths. The two main subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). While most research has focused on ESCC, few studies have analyzed EAC for transcriptional signatures linked to diagnosis or prognosis. In this study, we utilized single-cell RNA sequencing and bulk RNA sequencing to identify specific immune cell types that contribute to anti-tumor responses, as well as differentially expressed genes (DEGs). We have characterized transcriptional signatures, validated against a wide cohort of TCGA patients, that are capable of predicting clinical outcomes and the prognosis of EAC post-surgery with efficacy comparable to the currently accepted prognostic factors. In conclusion, our findings provide insights into the immune landscape and therapeutic targets of EAC, proposing novel immunological biomarkers for predicting prognosis, aiding in patient stratification for post-surgical outcomes, follow-up, and personalized adjuvant therapy decisions.
食管癌是一种高致死性恶性肿瘤，占所有癌症相关死亡的5%。其主要亚型包括食管鳞状细胞癌（ESCC）和食管腺癌（EAC）。尽管多数研究集中于ESCC，但针对EAC诊断或预后相关转录特征的分析仍较为有限。本研究通过单细胞RNA测序和批量RNA测序技术，鉴定了参与抗肿瘤反应的特异性免疫细胞类型及差异表达基因（DEGs）。我们系统表征了EAC的转录特征，并在TCGA大规模患者队列中验证了其预测临床结局及术后预后的能力，其效能与当前公认的预后因素相当。综上所述，本研究揭示了EAC的免疫微景观与治疗靶点，提出了新型免疫学生物标志物，可用于预后预测、术后结局患者分层、随访监测及个体化辅助治疗决策。
Definition of a Multi-Omics Signature for Esophageal Adenocarcinoma Prognosis Prediction
肿瘤(癌症)患者之家